Altered tumor vessel maturation and proliferation in placenta growth factor‐producing tumors: Potential relationship to post‐therapy tumor angiogenesis and recurrence
Open accessThe DOI matches its Crossref record.
Abstract
Cells in human tumor xenografts express similar levels of angiogenic growth factors before treatment. After radioimmunotherapy (RAIT) surviving tumor cells upregulate angiogenic growth factors, including placenta growth factor (PlGF), in a tumor‐specific pattern. To determine the role of post‐treatment PlGF expression on blood vessel recovery, tumor xenografts were assayed for post‐RAIT vessel density (CD34+), proliferation (PCNA+) and maturity (SMA+ pericytes/mural cells). To further analyze the role of PlGF in blood vessel formation, PlGF‐containing Matrigel implants were also assessed in a similar manner. The xenografts producing post‐treatment PlGF increased CD34+ microvessel density 2‐ to 4‐fold over untreated controls (p < 0.05) within 3 weeks of RAIT treatment. The proportion of mature microvessels (SMA+) decreased. Pericyte coverage and density of microvessels remained stable in the tumor that expressed neither PlGF nor VEGF after treatment. Hemoglobin content of PlGF‐containing Matrigel implants was 5.7‐fold that of anti‐PlGF/anti‐VEGF treated controls (Day 6, p < 0.03). The vessel density in PlGF‐implants averaged 36.8 ± 10.6/mm compared to 4.9 ± 6.5/mm 2 in controls (p < 0.001). Vessels of PlGF‐implants were lined by vWF+ cells, which were mostly flt‐1+. These findings point to a role for PlGF in rapid restoration of tumor blood supply after treatment and thus, to enhanced likelihood of tumor regrowth. Likewise, the cells of primary human tumors that upregulate PlGF after treatment may be more likely to survive and form recurring tumors. Prevention of this angiogenic response to treatment may require administration of anti‐angiogenic therapy during, rather than after, treatment. © 2003 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels
Fischer, C., Jonckx, B., Mazzone, M., Zacchigna, S., Loges, S., Pattarini, L., Chorianopoulos, E., Liesenborghs, L., Koch, M., De Mol, M., et al. (2007) · Cell · doi:10.1016/j.cell.2007.08.038 · Cited by 779
The angiogenic switch in carcinogenesis
Baeriswyl, V., & Christofori, G. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2009.05.003 · Cited by 625
FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?
Fischer, C., Mazzone, M., Jonckx, B., & Carmeliet, P. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2524 · Cited by 568
Nillesen, S. T. M., Geutjes, P. J., Wismans, R., Schalkwijk, J., Daamen, W. F., & van Kuppevelt, T. H. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2006.10.029 · Cited by 419
Anti-angiogenic therapy: current challenges and future perspectives
Lopes-Coelho, F., Martins, F., Pereira, S. A., & Serpa, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073765 · Cited by 416
“Despite the existence of other signaling pathways involved in angiogenesis, VEGF/VEGFRs interaction has been considered as a key regulator and constituted an attractive and central target for the development of anti-angiogenic drugs [18–22], the blockade of VEGF signaling pathway by neutralizing antibodies to VEGF or…”
Background
Metadata
- Authors
- Taylor, A. P., Rodriguez, M., Adams, K., Goldenberg, D. M., & Blumenthal, R. D.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2003-03-31
- Volume
- 105
- Issue
- 2
- Pages
- 158-164
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2070290363
- Cited by
- 58
- References
- 0
- FWCI
- 0.97
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Altered tumor vessel maturation and proliferation in placenta growth factor‐producing tumors: Potential relationship to post‐therapy tumor angiogenesis and recurrence. https://app.cochat.ai/papers/10.1002/ijc.11059
- The paper
- Taylor, A. P., Rodriguez, M., Adams, K., Goldenberg, D. M., & Blumenthal, R. D. (2003). Altered tumor vessel maturation and proliferation in placenta growth factor‐producing tumors: Potential relationship to post‐therapy tumor angiogenesis and recurrence. International Journal of Cancer. https://doi.org/10.1002/ijc.11059
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.